Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Best Practices for NHP Necropsy and Tissue Fixation to Ensure High-Quality Histology for Gene Therapies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Best Practices for NHP Necropsy and Tissue Fixation to Ensure High-Quality Histology for Gene Therapies

NHP Necropsy and Tissue Fixation Protocols for Gene Therapy Histology

CELL & GENE | RNA | BIOLOGICS

    Why is rapid tissue fixation important for AAV gene therapy studies?

    A: Rapid fixation via systemic perfusion prevents post-mortem autolysis, which can degrade tissues and compromise the integrity of molecular endpoints. This process is necessary for preserving transgene products (mRNA, proteins) and ensuring the accurate histological assessment of vector biodistribution and expression.

    What is the optimal fixative for preserving both morphology and molecular signals?

    A: 10% Neutral Buffered Formalin (NBF) delivered via perfusion is the industry standard for preserving tissue morphology for routine histology. However, protocol design for studies requiring specific molecular analyses may necessitate alternative fixatives or specialized handling to optimize signal detection for techniques like in situ hybridization or quantitative PCR.

    How does necropsy technique impact histology outcomes in NHP models?

    A: The precision, speed, and standardization of the necropsy directly determine data quality. A systematic, pre-defined tissue collection sequence minimizes artifacts and post-mortem intervals. This consistency provides the basis for comparing vector performance and safety profiles across study cohorts, particularly for evaluating non-target tissue biodistribution.

The quality of histology data from non-human primate (NHP) gene therapy studies is determined long before a slide reaches the microscope. Data integrity depends directly on the precision of the necropsy and the rigor of the tissue fixation protocol. Deficiencies in these early-stage procedures can introduce artifacts that generate uninterpretable data, compromising study objectives and program timelines.

Optimizing Tissue Handling for AAV Biodistribution Studies

For novel adeno-associated virus (AAV) vectors, histological analysis is a primary method for evaluating transduction efficiency and safety. A successful study requires a direct correlation between cellular-level gene expression and broader tissue-level outcomes. The ability to correlate cellular transduction with tissue-level results is a key factor in evaluating vector performance and selecting viable clinical candidates (PMID: 22849678). This requires tissue samples free from artifacts introduced by poor collection or handling.

A disciplined approach to necropsy and fixation ensures that the biological story told by the tissue is accurate. A successful program relies on a purpose-built infrastructure for complex biologics and a deep understanding of how preclinical variables influence regulatory review.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Standardizing Necropsy and Fixation for Interpretable Data

To generate reliable histology data for an Investigational New Drug (IND) application, every step of the tissue handling process must be standardized and executed with precision.

  • Systemic Perfusion: For NHP studies, whole-body perfusion with 10% NBF is the standard. This technique rapidly delivers fixative throughout the vasculature, preventing autolysis in the core of large organs and ensuring uniform preservation across all tissues.

  • Tissue Collection Hierarchy: A pre-defined tissue collection plan, organized by priority and anatomical location, minimizes the post-mortem interval for the most sensitive tissues. This systematic approach ensures consistency from one animal to the next.

  • Fixation Volume and Duration: Tissues should be placed in a volume of fixative at least 10 to 20 times that of the tissue itself. Inadequate fixative volume or duration leads to incomplete preservation, while excessive fixation can mask antigenic sites needed for immunohistochemistry (IHC).

  • Standardized Trimming: Proper orientation of tissues during gross trimming and embedding is a key determinant of quality. This ensures that sections for microscopy provide the correct anatomical context for accurate interpretation by a pathologist.

From Protocol Design to Regulatory Submission

These rigorous technical procedures are a component of a broader strategy for preclinical optimization. As outlined in workshops focused on gene therapy best practices, robust preclinical data packages are a prerequisite for successful regulatory engagement (PMID: 25654329). At our >100,000 sq ft GxP-compliant facility, we integrate these protocols into every study, contributing to an average 18-24 month IND timeline for our partners. This focus on data quality underpins our 100% IND success rate for programs initiated since 2019. (The Franklin Biolabs brand was launched in 2024). Our approach provides rapid pathology insights accelerating preclinical readouts.

All in vivo research is conducted in full compliance with USDA regulations and applicable animal welfare standards. Our protocols are designed around the 3Rs (Reduction, Refinement, and Replacement) to ensure the highest standards of ethical and humane animal care.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities